Linagliptin Krka (Linagliptin)

Linagliptin is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

• Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon release.
• Monotherapy in patients inadequately controlled with diet and exercise: provides an oral option to lower HbA1c.
• Combination therapy with metformin or other antidiabetic agents: adds complementary glucose‑lowering effect.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, linagliptin increases circulating levels of GLP‑1 and GIP, leading to enhanced glucose‑dependent insulin secretion from pancreatic β‑cells and suppressed glucagon release from α‑cells, thereby reducing post‑prandial and fasting plasma glucose concentrations.

Adverse reactions reported with linagliptin are generally mild, but serious events can occur and should be monitored.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nasal passages and throat.
• Headache: transient cranial pain of varying intensity.
• Upper respiratory tract infection: symptoms such as cough and sore throat.
• Dizziness: sensation of light‑headedness or imbalance.
• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation.
• Severe allergic reactions: including angioedema, urticaria or anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions.
• Hypoglycaemia (when combined with insulin or sulfonylureas): marked low blood glucose levels.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.

• Renal impairment: use with caution and monitor renal function, although dose adjustment is generally not required.
• Hepatic impairment: assess liver function and monitor for signs of hepatic injury.
• Cardiovascular disease: evaluate cardiovascular status as patients may have co‑existing conditions.
• Pregnancy: safety category is unknown; avoid use unless potential benefit justifies the risk.
• Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose closely.
• Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Linagliptin may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Insulin therapy: combined use can increase the risk of hypoglycaemia.
• Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may raise linagliptin plasma concentrations.
• Rifampicin or other potent enzyme inducers: can reduce linagliptin exposure and diminish glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

• Sulfonylureas (e.g., glimepiride): monitor for hypoglycaemia and adjust dose if needed.
• Diuretics: assess volume status and electrolytes as blood glucose changes may affect fluid balance.
• ACE inhibitors or ARBs: observe blood pressure and renal function when used together.
• Other DPP‑4 inhibitors: avoid concurrent use to prevent additive effects.